Premium
Toll‐like receptors 2 and 4 are involved in cardiomyocyte hypertrophy in vitro
Author(s) -
Gailser-Silva Fernanda,
Carneiro-Ramos Marcela Sorelli
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.lb623
Subject(s) - tlr2 , tlr4 , receptor , in vitro , agonist , collagenase , innate immune system , toll like receptor , muscle hypertrophy , biology , messenger rna , medicine , endocrinology , andrology , chemistry , microbiology and biotechnology , pharmacology , gene , biochemistry , enzyme
Objective The innate immune response can exerts innumerous effects in vast number of tissues and organs. It's well established that cytokines and Toll‐like receptors (TLRs) participate of cardiac trophism modulation. The objective of this study is to evaluate the effect of agonists of TLR 2 and 4 modulating cardiomyocyte trophism in vitro. Methods Primary cultures of cardiomyocytes were prepared from neonatal ventricles of Wistar rats by collagenase/pancreatin method. Cardiomyocytes primary cultures were treated for 24hs with LPS (1μM – TLR4 agonist), Zymozan (Zym 10μM – TLR2 agonist) or LPS + Zym combined. ANF and Alpha‐actin mRNA levels were used as cardiac hypertrophy markers. Gene expression was evaluated by Real‐time PCR. The results were expressed as mean±SD and P<0.05. Results The LPS and Zym promoted an increase on ANF and alpha‐actin expression (p<0.05). The administration of LPS combined with Zym did not potentiate this effect. The MyD88 mRNA levels, an adaptor protein of TLR cascade, were increase after both LPS (30%) and Zym (50%) treatment compared to control cells. These results suggest an important role for TLRs in cardiomyocyte hypertrophy in vitro. Financial Support: FAPESP.